Clinical trial

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

NCT05857085

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-12-15

PhasePHASE4

Study timeline

Study start (actual)2021-12-15Date precision: day

Registry last updated2023-05-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Endothelial Dysfunctionunresolved

Diabetes Mellitus, Type 1unresolved

Biomarkersunresolved

Endothelial Progenitor Cellsunresolved

SGLT 2 Inhibitorsunresolved

Incretinsunresolved

Glucose Excursionsunresolved

FMDunresolved

FPFunresolved

Arterial Stiffnessunresolved

Interventions

Semaglutide Pen Injector [Ozempic]DRUG · verified · RxNorm: semaglutide Pen Injector [Ozempic]

Empagliflozin 10 MGDRUG · verified · RxNorm: empagliflozin 10 MG

Sponsors & collaborators

General and Teaching Hospital Celjelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05857085 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.